文献
J-GLOBAL ID:202202281930819090
整理番号:22A0747788
完全ヒトBCMA標的CAR(CT103A)T細胞免疫療法の長期持続可能性のモデル展望説明【JST・京大機械翻訳】
A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
著者 (26件):
Mu Wei
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Mu Wei
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Long Xiaolu
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Long Xiaolu
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Cai Haodong
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Cai Haodong
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Chen Caixia
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Chen Caixia
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Hu Guang
(3Nanjing IASO Biotherapeutics Ltd., Nanjing, China)
,
Lou Yaoyao
(4Department of Hematology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China)
,
Xing Shugang
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Xing Shugang
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Wang Di
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Wang Di
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Wang Jue
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Wang Jue
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Xiao Min
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Xiao Min
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Wang Kun
(5Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China)
,
Sun Zhongyi
(5Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China)
,
Li Chunrui
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Li Chunrui
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Zhou Jianfeng
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Zhou Jianfeng
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
,
Chen Liting
(1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China)
,
Chen Liting
(2Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China)
資料名:
Frontiers in Pharmacology (Web)
(Frontiers in Pharmacology (Web))
巻:
13
ページ:
803693
発行年:
2022年
JST資料番号:
U7091A
ISSN:
1663-9812
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
スイス (CHE)
言語:
英語 (EN)